Disorders of pigmentation: Unapproved treatments

Clinics in Dermatology

Volumn 20, Issue 6, 2002, Pages 649-659

  Katsambas, Andreas ^a,b   Stefanaki, Christine ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIOL; ANDROSTENEDIONE; ASCORBIC ACID; ASTRAGALUS MEMBRANACEUS EXTRACT; AZELAIC ACID; BERGAPTEN; BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; ESTRONE; FLUTICASONE PROPIONATE; GLYCYRRHIZA EXTRACT; HYDROQUINONE; ISOTRETINOIN; KHELLIN; KOJIC ACID; MELANIN; METHOXSALEN; MINOXIDIL; OPHIOPOGON ROOT; PHENYLALANINE; PREGNENOLONE; PSORALEN DERIVATIVE; RETINOIC ACID; SEX HORMONE; TESTOSTERONE; TRIAMCINOLONE; TRIBULUS TERRESTRIS EXTRACT; TRIOXALEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ATROPHY; AUTOTRANSPLANTATION; BURNING SENSATION; CARBON DIOXIDE LASER; CARCINOGENIC ACTIVITY; CELL PROLIFERATION; CHLOASMA; CLIMATOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DEPIGMENTATION; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; ERBIUM YAG LASER; ERYTHEMA; HUMAN; LOW LEVEL LASER THERAPY; MELANOCYTE; META ANALYSIS; NAUSEA; PHOTOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; RELAPSE; REVIEW; SIDE EFFECT; SKIN ABRASION; SKIN ATROPHY; TELANGIECTASIA; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITILIGO;

EID: 0036864140     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00286-9     Document Type: Article

References (149)

1. Li V.W., Jaffe M.P., Li W.W., et al. Off label dermatologic therapies. Usage, risks and mechanisms. Arch Dermatol. 134:1998;1449-1454.
2. Mosher D.B., Fitzpatrick T.B., Ortonne J.P., et al. Hypomelanosis and hypermelanosis Vitiligo . Fitzpatrick T.B., Eisen A.Z., Wolff K., et al. Dermatology in General Medicine. 1999;945-1017 McGraw-Hill, New York.
3. Howitz J., Brdthagen H., Schwartz M., et al. Prevalence of vitiligo. Arch Dermatol. 113:1977;47-52.
4. Kovacs S.O. Vitiligo. J Am Acad Dermatol. 38:1998;647-666.
5. Shaffrali F.C.G., Gawkrodger D.J. Management of vitiligo. Clin Exp Dermatol. 25:2000;575-579.
6. Antoniou C.h, Katsambas A. Guidelines for the treatment of Vitiligo. Drugs. 43:1992;490-498.
7. Porter J.R., Mawr B., Hill-Beuf A., et al. Response to cosmetic disfigurement Patients with vitiligo . Cutis. 39:1987;493-494.
8. Levy S.B. Tanning preparations. Dermatol Clin. 18:2000;591-596.
9. Reiger M.M. The chemistry of tanning. Cosmetics Toiletries. 98:1983;47-50.
10. Westerhof W., Nieuweboer-Krobotova L., Mulder P.G., Glazenburg E.J. Left-right comparison study of the combination of fluticasone propionate and UVA vs either fluticasone propionate or UVA alone for long-term treatment of vitiligo. Arch Dermatol. 135:1999;1061-1066.
11. Khalid M., Mujtaba G. Response of segmental vitiligo to 0.05% clobetasol propionate cream. Int J Dermatol. 37:1998;701-708.
12. Mohrenschlager M., Schnopp C., Abeck D. Guidelines for treatment of vitiligo Is an update pending if recommendations for children are not followed? Arch Dermatol. 136:2000;1173.
13. Bleehen S.S. The treatment of vitiligo with topical corticosteroids Light and electron microscopic studies . Br J Dermatol. 94:(Suppl):1976;43-50.
14. Koopmans van Dorp B., Goedhart van Dijk B., Neering H., Van Dick E. Treatment of vitiligo by topical application of betamethasone 17-valerate in a dimethylsulphoxide cream base. Dermatologica. 146:1973;310-314.
15. Kandil E. Treatment of vitiligo with 0.1% betamethasone 17-valerate in isopropyl alcohol A double blind trial . Br J Dermatol. 91:1974;457-460.
16. Clayton R. Adouble blind trial of 0.05% clobetasol propionate in the treatment of vitiligo. Br J Dermatol. 96:1977;71-73.
17. Kandil E. Treatment of localized vitiligo with intradermal injections of triamcinolone acetonide. Dermatologica. 140:1970;195-206.
18. Goldstein E., Haberman H.F., Menon I.A., Pawlowski D. Non psoralen treatment of vitiligo. Part I. Cosmetics, Systemic coloring agents and corticosteroids. Int J Dermatol. 31:1992;229-236.
19. Vasistha L.K., Singh G. Vitiligo and intralesional steroids. Indian J Med Res. 69:1979;308-311.
20. Imamura S., Tagami H. Treatment of vitiligo with oral corticosteroids. Dermatologica. 153:1976;179-185.
21. Brotoff H., Brostoff J. Vitiligo and steroids. Lancet. 2:1978;688.
22. Kim S.M., Lee H.S., Hann S.K. The efficacy of low dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol. 38:1999;546-550.
23. Pasricha J.S., Khaitan B.K. Oral mini pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol. 32:1993;753-757.
24. Kanwar A.J., Dhar S., Dawn G. Oral mini pulse therapy in vitiligo. Dermatology. 190:1995;251-252.
25. Radakovic-Fijan S., Furnsinn-Friedl A., Honigsmann H., Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 44:2001;814-817.
26. Njoo M.D., Spuls P.I., Bos J.D., et al. Nonsurgical repigmentation therapies in vitiligo. Arch Dermatol. 134:1998;1532-1540.
27. Ichimiya M. Immunohistochemical study of ACTH and a-MSH in vitiligo patients successfully treated with a sex steroid-thyroid hormone mixture. J Dermatol. 26:1999;502-506.
28. Muto M., Furumoto H., Ohmura A., Asagami C. Successful treatment of vitiligo with a sex steroid-thyroid hormone mixture. J Dermatol. 22:1995;770-772.
29. Gokhale B., Goghale T. Corticotrophin and vitiligo (preliminary observations). Br J Dermatol. 69:1976;308-311.
30. Honig B., Morison W.L., Karp D. Photochemotherapy beyond psoriasis. J Am Acad Dermatol. 31:1994;775-790.
31. Cardoso C.A.L., Vilegas W., Honda N.K. Rapid determination of furocoumarins in creams and pomades using SPE and GC. J Pharm Biom Analysis. 22:2000;203-214.
32. Ernst E. Adverse effects of herbal drugs in dermatology. Br J Dermatol. 143:2000;923-929.
33. Lin Z.X., Hoult J.R.S., Raman A. Sulphordamine B assay for measuring proliferation of a pigmented melanocyte cell line and its application to the evaluation of crude drugs used in the treatment of vitiligo. J Ethnopharmacol. 66:1999;141-150.
34. Katsambas A.D., Lotti T.M., Ortonne J.P. Vitiligo. Katsambas A.D., Lotti T.M. European Handbook of Dermatological Treatments. 1999;617-623 Springer, Berlin.
35. Camacho F., Mazuecos J. Treatment of vitiligo with oral and topical phenylalanine 6 years of experience . Arch Dermatol. 135:1999;216-217.
36. Ryan W.L., Carver M.J. Inhibition of antibody synthesis by L-phenylalanine. Science. 43:1964;479-480.
37. Westerhof W., Groot I., Krieg S.R., et al. Langerhans' cell population studies with OKT6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA radiation. Acta Dermatol Venereol. 66:1986;259-274.
38. Antoniou C., Schulpis C.H., Michas I., et al. Vitiligo therapy with oral and topical phenylalanine with UVA exposure. Int J Dermatol. 28:1989;545-547.
39. Cormane R.H., Siddiqui A.H., Nengerman I.M. Photochemotherapy of vitiligo with oral phenylalanine. J Invest Dermatol. 80:1983;367.
40. Cormane R., Siddiqui A., Westerhof W., et al. Phenylalanine and UVA light for the treatment of vitiligo. Arch Dermatol Res. 277:1985;126-130.
41. Schulpis C.H., Antoniou C., Michas T., et al. Phenylalanine plus ultraviolet light preliminary report of promising treatment for childhood vitiligo . Pediatr Dermatol. 6:1989;332-335.
42. Siddiqui A.H., Stolk L.M.L., Bhaggoe R., et al. L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology. 188:1994;215-218.
43. Burkhart CG, Burkhart CN. Phenylalanine with UVA for the treatment of vitiligo needs more testing for possible side effects. J Am Acad Dermatol 40:1015.
44. Srinivas C., Shenoi S., Blachandran C. Acceleration of repigmentation in vitiligo by topical minoxidil in patients on photochemotherapy. Int J Dermatol. 29:1990;14-15.
45. Yalcin B., Sahin S., Bukulmez G., Karaduman A. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone A preliminary study . J Am Acad Dermatol. 44:2001;634-637.
46. Parsad D., Saini R., Nagpal R. Calcipotriol in vitiligo A preliminary study . Pediatr Dermatol. 16:1999;317-320.
47. Parsad D., Saini R., Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology. 197:1998;167-170.
48. Ameen M., Exarchou V., Chu A. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol. 145:2001;476-479.
49. 3 receptors in normal and psoriatic skin. J Invest Dermatol. 97:1991;230-239.
50. Schallreuter K.U., Pittelkow M.R., Swanson N.N. Defective calcium transport in vitiliginous melanocytes. Arch Dermatol Res. 288:1996;11-13.
51. Scherschun L., Kim J.J., Lim H.W. Narrow-band ultraviolet B is a useful and well tolerated treatment for vitiligo. J Am Acad Dermatol. 44:2001;999-1003.
52. Westerhof W., Nieuweboer-Krobotova L. Treatment of vitiligo with UVB radiation vs topical psoralen plus UVA. Arch Dermatol. 133:1997;1525-1528.
53. Njoo M.D., Bos J.D., Westerhof W. Treatment of generalized vitiligo in children with narrow band (TL-01) UVB radiation therapy. J Am Acad Dermatol. 42:2000;245-253.
54. Njoo M.D., Westerhof W., Bos J.D., Bossuyt P.M.M. The development of guidelines for the treatment of vitiligo. Arch Dermatol. 135:1999;1514-1521.
55. Imokawa G., Miyagishi M., Yada Y. Endothelin-1 as new melanogen Coordinated expression of its gene and the tyrosinase gene in UVB-exposed human epidermis . J Invest Dermatol. 105:1995;32-37.
56. Lotti T.M., Menchini G., Andreassi L. UVB radiation microphototherapy. An elective treatment for segmental vitiligo. J Eur Acad Dermatol. 13:1999;102-108.
57. Schallreuter K.U., Wood J.M., Lemke K.R., et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short term UVB exposure A case study on 33 patients . Dermatology. 190:1995;223-229.
58. 2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB activated pseudocatalase. J Invest Dermatol Symp Proc. 4:1999;91-96.
59. Schallreuter K.U. Successful treatment of oxidative stress in vitiligo. Skin Pharmacol Appl Skin Physiol. 12:1999;132-138.
60. Mofty M., Zaher H., Esmat S., et al. PUVA and PUVB in vitiligo - are they equally effective? Photodermatol Photoimmunol Photomed. 17:2001;159-163.
61. Juhlin L., Olsson M.J. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol. 77:1997;460-462.
62. Montes L.F., Diaz M.L., Lajous J., et al. Folic acid and vitamin B12 in vitiligo a nutritional approach. Cutis. 50:1992;39-42.
63. Baltas E., Nagy P., Bonis B., Novak Z. Repigmentation of localized vitiligo with the xenon chloride laser. Br J Dermatol. 144:2001;1266-1267.
64. Nihei Y., Nishibu A., Kaneko F. Sulplast Tosilate (IPD), a new immunoregulator is effective in vitiligo treatment. J Dermatol. 25:1998;250-255.
65. Pawelek J.M., Orlow S.J., Osber M.P. Synthesis and characterization of melanins from dihydroxyindol-2-carboxylic acid and dihydroxyindole. Pigment Cell Res. 5:1992;113-121.
66. Pasricha J.S., Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int J Dermatol. 33:1994;584-587.
67. Gianada B., Ortonne J.P., Thivolet J. Essai de traitement du vitiligo par l' association DCNB-PUVA. Ann Dermatol Venereol. 107:1980;197-198.
68. Shenefelt P.D. Hypnosis in dermatology. Arch Dermatol. 136:2000;393-399.
69. Halevy S., Sukenik S. Different modalities of spa therapy for skin diseases at the dead Sea Area. Arch Dermatol. 134:1998;1416-1420.
70. Njoo M.D., Bossuyt P.M., Westerhof W. Management of vitiligo. Results of a questionnaire among dermatologists in the Netherlands. Int J Dermatol. 38:1999;866-872.
71. Njoo M.D., Westerhof W., Bos J.D., Bossuyt P.M.M. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol. 134:1998;1543-1549.
72. Van Geel N., Ongenae K., Naeyaert J.M. Surgical techniques for vitiligo; A review. Dermatology. 202:2001;162-166.
73. Boersma B.R., Westerhof W., Bos J.D. Repigmentation in vitiligo vulgaris by autologous minigrafting Results in nineteen patients . J Am Acad Dermatol. 33:1995;990-995.
74. Falabella R. Treatment of localized vitiligo by autologous minigrafting. Arch Dermatol. 124:1988;1649-1655.
75. Malakar S., Dhar S. Treatment of stable and recalcitrant vitiligo by autologous miniature punch grafting A prospective study of 1000 patients . Dermatology. 198:1999;133-139.
76. Olsson M., Juhlin L. Epidermal sheet grafts for repigmentation of vitiligo and piebaldism, with a review of surgical techniques. Acta Dermatol Venereol. 77:1997;463-466.
77. McGovern T.W., Bolognia J., Leffell D.J. Flip-top pigment transplantation. Arch Dermatol. 135:1999;1305-1307.
78. Andreassi L., Pianigiani E., Andreassi A., et al. A new model of epidermal culture for the surgical treatment of vitiligo. Int J Dermatol. 37:1998;595-598.
79. Gupta S., Shroff S., Gupta S. Modified technique of suction blister for epidermal grafting in vitiligo. Int J Dermatol. 38:1999;306-309.
80. Skouge J., Morison W.L. Vitiligo treatment with a combination of PUVA therapy and epidermal autografts. Arch Dermatol. 131:1995;1257-1258.
81. Hann S.K., Im S., Bong H.W., Park Y.K. Treatment of stable vitiligo with autologous epidermal grafting and PUVA. J Am Acad Dermatol. 32:1995;943-948.
82. Sachdev M., Krupashankar D.S.R. Suction blister grafting for stable vitiligo using pulsed erbium-Yang laser ablation for recipient site. Int J Dermatol. 39:2000;471-473.
83. Kahn A.M., Ostad F.A., Moy R.L. Grafting following short pulse carbon dioxide laser de-epithelialization. Derm Surg. 22:1996;965-968.
84. Lee A., Jang J. Autologous epidermal epidermal grafting with PUVA - irradiated donor skin for the treatment of vitiligo. Int J Dermatol. 37:1998;551-554.
85. Falabella R., Escobar C., Borrero I. Treatment of refractory and stable vitiligo by transplantation of in vitro cultured epidermal autografts bearing melanocytes. J Am Acad Dermatol. 26:1992;230-236.
86. Guerra L., Cappuro S., Melchi F., et al. Treatment of stable vitiligo by Timedsurgery and transplantation of cultured epidermal autografts. Arch Dermatol. 136:2000;1380-1389.
87. Gauthier Y., Surleve-Bazeille J.E. Autologous grafting with non-cultured melanocytes A simplified method for treatment of depigmented lesions . J Am Acad Dermatol. 26:1992;191-194.
88. Olsson M.J., Juhlin L. Leucoderma treated by transplantation of a basal cell layer enriched suspension. Br J Dermatol. 138:1998;644-648.
89. Chen Y., Chang J.S., Yang P., et al. Transplant of cultured autologous pure melanocytes after laser ablation for the treatment of segmental vitiligo. J Dermatol. 27:2000;434-439.
90. Kaufmann R., Greiner D., Kippenberger S., Bernd A. Grafting of in vitro cultured melanocytes onto laser-ablated lesions in vitiligo. Acta Derm Venereol. 78:1998;136-138.
91. Chen Y., Yang P., Hung C., Hu D. Transplantation of autologous cultured melanocytes for treatment of large segmental vitiligo. J Am Acad Dermatol. 44:2001;543-545.
92. Ongenae K., Van Geel N., Naeyaert J.M. Autologous cellular suspensions and sheets in the treatment of achromic disorders The need for future controlled studies . Dermatology. 202:2001;158-161.
93. Malakar S., Dhar S. Repigmentation of vitiligo patches by transplantation of hair follicles. Int J Dermatol. 38:1999;237-238.
94. Na G, Seo SK, Choi SK. Single hair grafting for the treatment of vitiligo. J Am Acad Dermatol 38:580-4.
95. Malakar S., Lahiri K., Malakar R.S. How unstable is the concept of stability in surgical repigmentation of vitiligo. Dermatology. 201:2000;182-183.
96. Njoo M.D., Vodegel R.M., Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol. 42:2000;760-769.
97. Katsambas A.D., Lotti T.M. Melasma. Katsambas A.D., Lotti T.M. European Handbook of Dermatological Treatments. 1999;368-373 Springer, Berlin.
98. Peraz M., Sanchez J.L., Aquilo F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol. 81:1983;543-545.
99. Lufti R.J., Fridmanis M., Misrunas A.L., et al. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of melasma. J Clin Endocrinol Metab. 61:1985;28-31.
100. Sanchez N.P., Pathak M.A., Sato S., et al. Melasma A clinical light microscopic, ultrastructural and immunofluorescence study . J Am Acad Dermatol. 4:1981;698-710.
101. Jimbow M., Jimbow K. Pigmentary disorders in Oriental skin. Clin Dermatol. 7:1989;11-27.
102. Gilchrist B.A. Localization of melanin pigmentation with Wood's lamp. Br J Dermatol. 96:1977;245-248.
103. Grimes P.E. Melasma Etiologic and therapeutic considerations . Arch Dermatol. 131:1995;1453-1457.
104. Arndt K.A., Fitzpatrick T.B. Topical use of hydroquinone as a depigmenting agent. JAMA. 194:1965;965-967.
105. Glenn M., Grimes P.E., Pitt E., et al. Evaluation of clinical and light microscopic effects of various concentrations of hydroquinone. (abstract) Clin Res. 39:1991;83A.
106. Clarys P., Barel A. Efficacy of topical treatment of pigmentation skin disorders with plant hydroquinone glycosides as assessed by quantitative color analysis. J Dermatol. 25:1998;412-414.
107. Kligman A.M., Willis I. A new formula for depigmenting human skin. Arch Dermatol. 11:1975;40-48.
108. Gano S.E., Garcia R.L. Topical tretinoin, hydroquinone and betamethasone valerate in the therapy of melasma. Cutis. 23:1979;239-241.
109. Pathak M.A., Fitzpatrick T.B., Kraus E.W. Usefulness of retinoic acid in thr treatment of melasma. J Am Acad Dermatol. 15:1986;894-899.
110. Kang W.H., Chun S.C., Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinine and hydrocortisone) Clinical and histological studies . J Dermatol. 25:1998;587-596.
111. Piamphongsant T. Treatment of melasma A review with personal experience . Int J Dermatol. 37:1998;897-903.
112. Guevara I.L., Pandya A.G. Melasma treated with hydroquinine, tretinoin and a fluorinated steroid. Int J Dermatol. 40:2001;210-215.
113. Bleehen S.S. The treatment of hypermelanosis with 4-isopropylcatechol. Br J Dermatol. 94:1976;687-694.
114. Fleischer A.B., Schwartzel E.H., Colby S.I., et al. The combination of 2% 4-hydroxyanisole (Mequinole) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicentre clinical studies. J Am Acad Dermatol. 42:2000;459-467.
115. Breathnach A.S., Diala E.B., Gallagher S.M., et al. Ultrastructural observations on the effect of 4-hydroxyanisole on normal human melanocytes in tissue culture. J Invest Dermatol. 77:1981;292-296.
116. Jimbow M. N-acetyl-4-S-cystaminylphenol as a new type of depigmenting agent for the treatment of patients with melasma. Arch Dermatol. 127:1991;1528-1534.
117. Griffiths C.E., Finkel L.T., Ditre C.M., et al. Topical tretinoin (retinoic acid) improves melasma A vehicle-controlled, clinical trial . Br J Dermatol. 129:1993;415-421.
118. Kimbrough-Green C.K., Griffiths C.E., Finkel L.J., et al. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol. 130:1994;727-733.
119. Bulengo-Ransby S.M., Griffiths C.E.M., Kimbrough-Green C.K., et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in Black patients. N Engl J Med. 328:1993;1438-1443.
120. Tadaki T, Watanabe M, Kumasaki K, et al. The effect of topical tretinoin on the photodamaged skin of the Japanese. Tohoku J Exp Med 1993;169:243-40.
121. Cuce L.C., Bertino M.C., Scattone L., Birkenhauer M.C. Tretinoin peeling. Dermatol Surg. 27:2001;608.
122. Leenutaphong V., Nettakul A., Rattanasuwon P. Topical isotretinoin for melasma in Thai patients A vehicle controlled clinical trial . J Med Assoc Thai. 82:1999;868-875.
123. Fitton A., Goa K.L. Azelaic acid. Drugs. 41:1991;780-798.
124. Bose S.K., Ortonne J.P. Pigmentation Dyschromia . Baran R., Maibach H. Textbook of Cosmetic Dermatology. 1998;391-415 Martin-Dunitz Ltd, London.
125. Verallo-Rowell V.M., Verallo V., Graupe K., et al. Double-blind comparison study of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl. 143:1989;58-61.
126. Balina L.M., Graupe K. The treatment of melasma with 20% azelaic acid vs 4% hydroquinone cream. Int J Dermatol. 30:1991;893-895.
127. Kahn V. Effect of kojic acid on the oxidation of DL-DOPA, norepinephrine and dopamine by mushroom tyrosinase. Pigment Cell Res. 8:1995;234-240.
128. Lim J.T. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 25:1999;282-284.
129. Garcia A., Fulton J.E. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 22:1996;443-447.
130. Westerhof W., Njoo M.D. Bleaching agents. Katsambas A.D., Lotti T.M. European Handbook of Dermatological Treatments. 1996;766-777 Springer, Berlin.
131. Kameyama K., Sakai C., Kondoh S., et al. Inhibitory effects of magnesium-L-ascorbyl-2-phosphate on melanogenesis in vitro and in vivo. J Am Acad Dermatol. 34:1996;29-33.
132. Draelos Z.D. Therapeutic moisturizers. Dermatol Clin. 18:2000;597-607.
133. Njoo M.D., Menke H.E., Pavel W., et al. N-acetylcysteine as a bleaching agent in the treatment of melasma. J Eur Acad Derm Venereol. 9:1997;86-87.
134. Yasuaki O. Liquitrin for the removal of stains from the skin. Chem Abstr. 117:1992;476.
135. Am M., Metwalli M. Topical liquitrin improves melasma. Int J Dermatol. 39:2000;299-301.
136. Bolognia J.L., Sodi S.A., Osber M.P., Pawelek J.M. Enhancement of the depigmenting effect of hydroquinone by cystamine and buthionine sulfoximine. Br J Dermatol. 133:1995;349-357.
137. Moy L.S., Murad H., Moy R. Glycolic acid peels for the treatment of wrinkles and photoaging. J Dermatol Surg Oncol. 19:1993;243-246.
138. Lawrence N., Cox S.E., Brody H.J. Treatment of melasma with Jessner's solution versus glycolic acid A comparison of clinical efficacy and evaluation of the predictive ability of Wood's light examination . J Am Acad Dermatol. 36:1997;589-593.
139. Cotellessa C., Peris K., Onorati M.T., et al. The use of chemical peelings in the treatment of different cutaneous hyperpigmentations. Dermatol Surg. 25:1999;450-454.
140. Karam P. 50% Resorcinol peel. Int J Dermatol. 32:1993;569-574.
141. Grimes P.E. The safety and efficacy of salicylic acid chemical peels in dark racial-ethnic groups. Dermatol Surg. 25:1999;18-22.
142. Kunachak S., Leelaudomlipi P., Wongwaisayawan S. Dermabrasion A curative treatment for melasma . Aesth Plast Surg. 25:2001;114-117.
143. Grekin R.C., Shelton R.M., Geisse J.K., Frieden I. 510 nm pigmented lesion dye laser its characteristics and clinical uses . J Dermatol Surg Oncol. 19:1993;380.
144. Taylor C.R., Anderson R.R. Ineffective treatment of refractory melasma and post-inflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol. 20:1994;592.
145. Goldberg D.J. Benign pigmented lesions of the skin Treatment with the Q-switched ruby laser . J Dermatol Surg Oncol. 19:1993;376.
146. Tse Y., Levine V.J., McClain S.A., Ashinoff R. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the neodymium:yitrium-aluminium-garnet laser. J Dermatol Surg Oncol. 20:1994;795.
147. Goldberg D.J. Laser treatment of pigmented lesions. Dermatol Clin. 15:1997;397-407.
148. 2 laser followed by Q-switched alexandrite laser A pilot study . Dermatol Surg. 25:1999;494-497.
149. Manaloto R.M., Alster T. Erbium-YAG laser resurfacing for refractory melasma. Dermatol Surg. 25:1999;121-123.